Veracyte chief scientific & med officer sells over $564k stock

Phillip G. Febbo, Veracyte's Chief Scientific and Medical Officer, sold 13,110 shares of the company's stock on September 4, 2026, for a total of $564,409. These sales were made in accordance with a pre-approved Rule 10b5-1 plan adopted by Mr. Febbo on August 21, 2025. The shares were sold at a weighted average price of $42.90 to $43.66 per share, as Veracyte's stock price was trading at $42.53, up 31% over the past year.

Despite the sale, Mr. Febbo still holds a total of 133,048 shares of Veracyte common stock, following the withholding of 3,639 shares on September 2, 2026, to cover tax obligations related to the vesting of restricted stock units. This withholding transaction was separate from the stock sales and did not involve a reduction in his ownership stake.

Veracyte recently reported strong second-quarter 2026 earnings, surpassing analysts' expectations with adjusted earnings of $0.54 per share and revenue of $150.3 million. The company has since raised its full-year revenue outlook, leading to supportive reactions from analysts such as Freedom Capital and Needham, who raised their price targets for the stock. However, Canaccord adjusted its price target downward, indicating varying opinions on the company's future revenue prospects.